S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
NASDAQ:YMTX

Yumanity Therapeutics - YMTX Competitors

$3.91
+0.73 (+22.96%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.50
$4.20
50-Day Range
$3.17
$8.33
52-Week Range
$0.95
$13.23
Volume
92,260 shs
Average Volume
473,083 shs
Market Capitalization
$42.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

YMTX vs. ELDN, ORGS, VTGN, CKPT, PTN, MNPR, SGTX, MEIP, LPTX, and UNCY

Should you be buying Yumanity Therapeutics stock or one of its competitors? The main competitors of Yumanity Therapeutics include Eledon Pharmaceuticals (ELDN), Orgenesis (ORGS), VistaGen Therapeutics (VTGN), Checkpoint Therapeutics (CKPT), Palatin Technologies (PTN), Monopar Therapeutics (MNPR), Sigilon Therapeutics (SGTX), MEI Pharma (MEIP), Leap Therapeutics (LPTX), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical preparations" industry.

Yumanity Therapeutics vs.

Yumanity Therapeutics (NASDAQ:YMTX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings.

Eledon Pharmaceuticals received 4 more outperform votes than Yumanity Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Yumanity Therapeutics an outperform vote while only 64.29% of users gave Eledon Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Yumanity TherapeuticsOutperform Votes
14
70.00%
Underperform Votes
6
30.00%
Eledon PharmaceuticalsOutperform Votes
18
64.29%
Underperform Votes
10
35.71%

Eledon Pharmaceuticals has a net margin of 0.00% compared to Yumanity Therapeutics' net margin of -660.61%. Eledon Pharmaceuticals' return on equity of -25.14% beat Yumanity Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Yumanity Therapeutics -660.61% -263.34% -107.08%
Eledon Pharmaceuticals N/A -25.14% -24.13%

Yumanity Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.

Eledon Pharmaceuticals has a consensus target price of $22.00, suggesting a potential upside of 746.15%. Given Eledon Pharmaceuticals' higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Yumanity Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Yumanity Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Eledon Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Eledon Pharmaceuticals has lower revenue, but higher earnings than Yumanity Therapeutics. Yumanity Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yumanity Therapeutics$4.84 million7.13-$39.50 million-$3.00-1.06
Eledon PharmaceuticalsN/AN/A-$34.51 million-$2.66-0.98

In the previous week, Eledon Pharmaceuticals had 3 more articles in the media than Yumanity Therapeutics. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 0 mentions for Yumanity Therapeutics. Eledon Pharmaceuticals' average media sentiment score of 0.22 beat Yumanity Therapeutics' score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Yumanity Therapeutics Neutral
Eledon Pharmaceuticals Neutral

25.1% of Yumanity Therapeutics shares are held by institutional investors. Comparatively, 45.6% of Eledon Pharmaceuticals shares are held by institutional investors. 12.5% of Yumanity Therapeutics shares are held by insiders. Comparatively, 13.8% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Eledon Pharmaceuticals beats Yumanity Therapeutics on 14 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

YMTX vs. The Competition

MetricYumanity TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$34.52M$5.47B$4.31B$5.88B
Dividend YieldN/A2.59%2.40%4.45%
P/E Ratio-1.064.52104.7412.59
Price / Sales7.13288.523,506.5356.17
Price / CashN/A19.3626.83101.17
Price / Book1.394.154.454.96
Net Income-$39.50M$186.79M$115.24M$190.78M
7 Day Performance-41.54%-4.10%-2.80%-1.29%
1 Month Performance-53.85%-10.97%-6.86%-6.81%
1 Year Performance79.66%-14.65%-16.20%-18.37%

Yumanity Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELDN
Eledon Pharmaceuticals
2.3842 of 5 stars
$2.50
+8.2%
$22.00
+780.0%
-31.7%$34.40MN/A-0.9412News Coverage
Gap Down
ORGS
Orgenesis
1.357 of 5 stars
$1.34
-6.3%
N/A-61.6%$34.24M$35.50M-2.53111Analyst Report
VTGN
VistaGen Therapeutics
1.0417 of 5 stars
$0.16
+14.7%
N/A-86.6%$34.15M$1.11M-0.5031News Coverage
Gap Down
High Trading Volume
CKPT
Checkpoint Therapeutics
2.0227 of 5 stars
$3.77
-1.3%
$23.50
+523.3%
+106.0%$35.06M$270,000.00-0.4314Upcoming Earnings
PTN
Palatin Technologies
1.4688 of 5 stars
$3.03
+5.2%
$50.00
+1,550.2%
+628.4%$33.79M$2.88M-0.98N/A
MNPR
Monopar Therapeutics
1.8808 of 5 stars
$2.73
-0.4%
$12.67
+364.0%
+3.0%$35.27MN/A-3.379News Coverage
SGTX
Sigilon Therapeutics
1.9277 of 5 stars
$1.09
-2.7%
$6.00
+450.5%
-25.9%$35.39M$12.94M-0.8166News Coverage
Gap Down
MEIP
MEI Pharma
1.9581 of 5 stars
$0.25
flat
$2.43
+871.0%
-86.4%$33.33M$40.70M-1.0976
LPTX
Leap Therapeutics
1.8557 of 5 stars
$0.34
flat
$2.80
+735.8%
-82.0%$33.17M$1.50M-0.7136Upcoming Earnings
UNCY
Unicycive Therapeutics
2.0309 of 5 stars
$2.20
-2.2%
$6.33
+187.9%
+67.9%$33.11MN/A-2.161Upcoming Earnings
This page (NASDAQ:YMTX) was last updated on 3/23/2023 by MarketBeat.com Staff